Added to YB: 2026-09-17
Pitch date: 2026-09-15
TLSI [neutral]
TriSalus Life Sciences, Inc.
Author Info
No bio for this author
Company Info
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Market Cap
$293.7M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-9.50
P/E
-4.15
EV/Sales
6.25
Sector
Biotechnology
Category
growth
Biotech Conference Coverage: Week 2, Day 1 — Part 2: TriSalus Life Sciences, Inc.
TLSI (quick overview): TriSalus is a differentiated interventional-oncology delivery-platform story and plausible takeout candidate, but 2026 is principally a sales-execution test. After more than doubling its sales force and disrupting roughly 40% of territories, Q2 revenue of $11.4-11.5M leaves a steep second-half ramp to reach $54-57M guidance. Near-term upside comes from expected TriNav Advance clearance and 2027 OBL reimbursement; nelitolimod is optionality rather than the core thesis.
Read full article (2 min)